A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study of the Safety and Efficacy of Daily CF101 Administered Orally, When Added to Weekly Methotrexate, in Patients With Active Rheumatoid Arthritis.
Phase of Trial: Phase II
Latest Information Update: 03 Apr 2018
At a glance
- Drugs Piclidenoson (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Can-Fite BioPharma
- 31 Aug 2018 Biomarkers information updated
- 17 Dec 2009 Actual end date (April 2009) added as reported by ClinicalTrials.gov.
- 17 Dec 2009 Additional trial locations identified as reported by ClinicalTrials.gov.